Please login to the form below

Not currently logged in
Email:
Password:

MHRA chair Breckenridge to advise UK on healthcare ethics

Sir Alasdair Breckenridge appointed first chair of the Emerging Science and Bioethics Advisory Committee

Professor Sir Alasdair Breckenridge - MHRA chairChair of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Sir Alasdair Breckenridge, has been appointed the first chair of the Emerging Science and Bioethics Advisory Committee at the country's Department of Health (DH).

The new committee has been formed to advise UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications.

"I am delighted that Sir Alasdair has agreed to chair this important new committee,” said the DH's chief medical officer, Dame Sally Davies.

“He brings with him a level of experience that is difficult to match, plus a reputation for delivering high calibre debate and advice on serious scientific issues.”

In addition to his MHRA experience, Sir Alasdair's previous roles include serving as a member of the Adverse Reactions Group, and the Subcommittee on Adverse Reactions to Vaccines and Immunisation of the MHRA precursor, the Committee on Safety of Medicines (CSM).

Between 1992 and 1996 he was a member of the Medical Research Council, and he has worked closely on several programmes of the European Union, the World Health Organization and the International Union of Pharmacology.

Sir Alasdair takes up the position immediately, and will remain in the role for two years while also serving for the MHRA.

23rd May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics